MedPath

A study to assess the effect of oral insulin on safety, tolerability, effect of oral insulin on the blood sugar level and effect of oral insulin on the body in typeI Diabetes mellitus patients.

Phase 1
Completed
Conditions
Health Condition 1: null- Type 1 Diabetes Mellitus
Registration Number
CTRI/2009/091/001008
Lead Sponsor
Biocon Research Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
28
Inclusion Criteria

1.Ready for written informed consent.

2.Patients of either gender between 18 to 45 years inclusive.

3.Established diagnosis of TIDM.

4.Body mass Index of 18.5-29.9kg/m2 inclusive.

5.Stable weight.

6.Glycosylated Haemoglobin (HbAIC) 8.0%at screening.

7.On stable insulin or an insulin analogue regimen for atleast 3 months.

Exclusion Criteria

•History of hypersensitivity to active or inactive ingredients of the drug

•Significant history of atopy or allergic drug reactions.

•Abnormal lab parameters â?? urine, ECG, hepatic and renal function

•History of drug or alcohol dependence or abuse within 6 months prior to screening.

•Insulin resistance

•Patients on glucocorticoids, other blood-glucose lowering drugs

•Uncontrolled hypertension and hyperlipidemia

•Evidence of severe secondary complications of diabetes

•History of hypoglycemia or hypoglycemia unawareness

•Any hospitalization or emergency room visit due to poor diabetes control within 6 months prior to screening.

•Diseases like coronary artery disease, history of stroke, hematological disorders, planned surgery

•Pregnancy, lactation, or planned pregnancy

•The patient has received another investigational drug

•Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.

Study & Design

Study Type
BA/BE
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
AUC ratio from 0-130 min for PK and PD with Lispro for different dosesTimepoint: 0-130 min
Secondary Outcome Measures
NameTimeMethod
Other PK primary and secondary parameters, PD and PK ratio of AUC at different other time intervals till 250 min <br/ ><br>Safety and tolerability <br/ ><br>Timepoint: 0-70min, o-190 min and 0-250 min
© Copyright 2025. All Rights Reserved by MedPath